Sign In
Buy LFCR
$5.67
+0.220 (+4.04%)
At Close: Jun 03, 2026
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
04:52pm, Monday, 16'th Mar 2026
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
04:05pm, Tuesday, 10'th Mar 2026
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CD
CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDM
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
04:03pm, Wednesday, 04'th Mar 2026
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug
Lifecore Biomedical to Participate at DCAT Week 2026
07:05am, Tuesday, 17'th Feb 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO
Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action settles.
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
05:09pm, Thursday, 29'th Jan 2026
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves
PHILADELPHIA, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ibotta, Inc. (NYSE: IBTA): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Ibotta, Inc. (NYSE: IBTA).
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:45pm, Friday, 16'th Jan 2026
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today an
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10:39am, Thursday, 15'th Jan 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary d
Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud
Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation conce
PHILADELPHIA, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investi
Lifecore Biomedical: The Turnaround Is Just Getting Started
08:50am, Thursday, 01'st Jan 2026
Lifecore Biomedical (LFCR) has completed its turnaround, emerging as a pure-play US-based CDMO with a cleaned-up balance sheet and high operational leverage. LFCR's new capacity is underutilized but a
